<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">mGluR3 Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Description</td>
</tr>
<tr>
<td class="label">N-terminal VFT domain</td>
<td>Large extracellular domain (~400 aa) with ligand binding site</td>
</tr>
<tr>
<td class="label">Cysteine-rich domain (CRD)</td>
<td>Flexible linker with structural disulfide bonds</td>
</tr>
<tr>
<td class="label">7 Transmembrane domain</td>
<td>Classic seven-helix bundle</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Contains serine/threonine phosphorylation sites</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">LY354740</td>
<td>mGluR2/3 agonist</td>
</tr>
<tr>
<td class="label">LY379268</td>
<td>mGluR2/3 agonist</td>
</tr>
<tr>
<td class="label">DCG-IV</td>
<td>mGluR2/3 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">VU06507876</td>
<td>mGluR3 PAM</td>
</tr>
<tr>
<td class="label">AV-101</td>
<td>mGluR3 PAM</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Primary Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Reduced signaling</td>
</tr>
<tr>
<td class="label">ERK/MAPK</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Enhanced sur
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">mGluR3 Protein</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Description</td>
</tr>
<tr>
<td class="label">N-terminal VFT domain</td>
<td>Large extracellular domain (~400 aa) with ligand binding site</td>
</tr>
<tr>
<td class="label">Cysteine-rich domain (CRD)</td>
<td>Flexible linker with structural disulfide bonds</td>
</tr>
<tr>
<td class="label">7 Transmembrane domain</td>
<td>Classic seven-helix bundle</td>
</tr>
<tr>
<td class="label">C-terminal tail</td>
<td>Contains serine/threonine phosphorylation sites</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">LY354740</td>
<td>mGluR2/3 agonist</td>
</tr>
<tr>
<td class="label">LY379268</td>
<td>mGluR2/3 agonist</td>
</tr>
<tr>
<td class="label">DCG-IV</td>
<td>mGluR2/3 agonist</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">VU06507876</td>
<td>mGluR3 PAM</td>
</tr>
<tr>
<td class="label">AV-101</td>
<td>mGluR3 PAM</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Primary Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Reduced signaling</td>
</tr>
<tr>
<td class="label">ERK/MAPK</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Enhanced survival</td>
</tr>
<tr>
<td class="label">NF-κB</td>
<td>Inhibited</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
mGluR3 (Metabotropic Glutamate Receptor 3), encoded by the GRM3 gene (also known as GRM3 or mGlu3), is a member of the Group II metabotropic glutamate receptor family. Unlike its close relative mGluR2, mGluR3 is predominantly expressed on glial cells—particularly astrocytes and microglia—rather than neurons. This unique cellular distribution positions mGluR3 as a critical regulator of neuroinflammation, glutamate homeostasis, and neuron-glia communication [@tattoli2024].
The receptor has attracted significant interest as a therapeutic target due to its roles in modulating inflammatory responses, regulating synaptic plasticity through glial mechanisms, and influencing neuronal survival pathways. GRM3 polymorphisms have been linked to schizophrenia, cognitive function, and susceptibility to neurodegenerative diseases, highlighting its importance in human health and disease [@pope2023].
The GRM3 gene (Gene ID: 2912) is located on chromosome 7q21.1-q21.2 in humans. The gene spans approximately 30 kb and contains 11 exons. Alternative splicing generates multiple mRNA variants with distinct expression patterns and functional properties. The GRM3 promoter contains regulatory elements that respond to neuronal activity, cytokines, and pathological conditions.
Key structural features:
mGluR3 shares the class C GPCR architecture with mGluR2:
The ligand binding pocket shows high affinity for glutamate, with binding kinetics that differ slightly from mGluR2. The receptor can form both homodimers and heterodimers with mGluR2, creating functionally distinct complexes.
mGluR3 can form:
mGluR3 exhibits distinctive cellular distribution: [@rossi2023]
mGluR3 plays a crucial role in maintaining glutamate balance:
mGluR3 is a key modulator of inflammatory responses: [@davidson2024]
Although primarily glial, mGluR3 influences synaptic plasticity indirectly: [@tang2023]
mGluR3 dysregulation contributes to AD pathogenesis: [@henneberry2023]
mGluR3 modulation offers several therapeutic strategies: [@chen2024]
mGluR3 plays important roles in PD: [@kim2024]
GRM3 is a well-established schizophrenia susceptibility gene: [@walker2022]
mGluR3 involvement in ALS: [@williams2024]
mGluR3 affects oligodendrocyte function: [@miller2023]
PAMs that enhance mGluR3 function:
NAMs have been explored for different indications: [@anderson2022]
mGluR3 couples primarily to Gi/o proteins: [@jackson2022]